secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2026-01-26T23:59:59+00:00
Accession:  0001658247-26-000003
Event type: leadership
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics changes Jeff Knight's title from COO to Chief Development and Operating Officer
--------------------------------------------------------------------------------

- Title change effective January 2, 2026; responsibilities expanded.
- No change to Jeff Knight's compensation arrangements.
- No arrangements or family relationships with other executives or directors.
- Business experience described in prior proxy statement remains unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000165824726000003/0001658247-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000165824726000003/crnx-20260120.htm
  HTML page:      https://secwatch.observer/filing/0001658247-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer